Intellikine commences INK1117 Phase I dose escalation study in cancer

[News]

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that the first patient has been treated in a Phase I dose escalation study of INK1117 in patients with advanced solid malignancies.

More... (http://www.news-medical.net/news/20111012/Intellikine-commences-INK1117-Phase-I-dose-escalation-study-in-cancer.aspx)